TPTX News and Press, Turning Point Therapeutics Inc. From 11/12/19

SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate repotrectinib in pediatric p...

SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its drug candidate TPX-0046 in patients with advance...

Turning Point Therapeutics, Inc. (TPTX) Q3 2019 Earnings Conference Call November 4, 2019 04:30 PM ET Company Participants Jim Mazzola - Senior Vice President, Communication and Investor Relations Athena Countouriotis - President and Chief Executive Officer Yi Larson - Executive ...

Image source: The Motley Fool. Turning Point Therapeutics Inc   (NASDAQ: TPTX) Q3 2019 Earnings Call Nov 4, 2019 , 4:30 p.m. ET Operator Continue reading

Turning Point Therapeutics (NASDAQ: TPTX ): Q3 GAAP EPS of -$0.63 misses by $0.07 . More news on: Turning Point Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Registrational Phase 2 Study of Repotrectinib Ongoing   Phase 1/2 Clinical Studies of RET/SRC Inhibitor TPX-0046 and Repotrectinib in Pediatric Patients On Track to Initiate in 2019   Mohammad Hirmand, M.D. Named Executive Vice President and Chief Medical Officer, Ef...

SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report third quarter financial results following the close of U.S. financial markets on Nov. 4 and host a c...

For an equity market that has hit all-time highs on multiple occasions during this year, one would think that investors would be salivating over IPOs for a chance to "get in from the beginning" and bidding them higher in the process. The reality, though, is that IPOs have been one of the more ...

Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...

The FDA clears Turning Point Therapeutics' (NASDAQ: TPTX ) IND for TPX-0046, a novel therapy targeting solid tumors with abnormal RET genes by inhibiting RET and SRC kinases. More news on: Turning Point Therapeutics, Inc., Healthcare stocks news, Read more ...